Three-Drug Regimen May Improve Survival Outcomes in Subset of Patients with Melanoma
Source: Cure Today, December 2022
Although triplet therapy may be effective and tolerable for patients with BRAF-mutant melanoma, each patient’s case should be considered before deciding if it is the right course of treatment, according to an expert.
Treatment with Tecentriq (atezolizumab) plus vemurafenib and Cotellic (cobimetinib) demonstrated an improvement in overall survival (time patient lives after diagnosis or treatment) for patients with BRAF-mutated melanoma, according to a recent second interim analysis.
“It is known that using targeted therapies with dual BRAF and MEK inhibitors in patients with BRAF-mutated melanoma that is unresectable or metastatic can lead to rapid, clinically meaningful responses,” Dr. Sunandana Chandra, associate professor in the division of hematology oncology at Northwestern University Feinberg School of Medicine in Chicago, told CURE® in an interview.